| dbo:abstract |
Bentracimab is a monoclonal antibody medication which has been shown in phase one and two clinical trials to function as a reversal agent for the anti–blood clotting drug ticagrelor (which acts as a P2Y12 inhibitor and is sold under the brand name Brilinta among others). It is under investigation for use in major, life-threatening bleeding in patients being treated with ticagrelor. It is not commercially available. (en) |
| dbo:casNumber |
2260568-31-6 |
| dbo:drugbank |
DB16659 |
| dbo:fdaUniiCode |
1TBM83QR9S |
| dbo:kegg |
D11799 |
| dbo:wikiPageID |
67699678 (xsd:integer) |
| dbo:wikiPageLength |
4252 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1107898866 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Antiplatelet_drug dbr:Antithrombotic dbr:Vitamin_K dbr:Ciraparantag dbr:Monoclonal_antibody dbr:Andexanet_alfa dbr:Clinical_trials dbr:Active_metabolite dbr:Ticagrelor dbc:Antidotes dbc:Monoclonal_antibodies dbr:Idarucizumab dbr:P2Y12 dbr:Intravenous_infusion |
| dbp:atcPrefix |
None (en) |
| dbp:c |
2095 (xsd:integer) |
| dbp:casNumber |
2260568 (xsd:integer) |
| dbp:drugbank |
DB16659 (en) |
| dbp:h |
3240 (xsd:integer) |
| dbp:kegg |
D11799 (en) |
| dbp:legalStatus |
Investigational (en) |
| dbp:mabType |
Fab (en) |
| dbp:n |
560 (xsd:integer) |
| dbp:o |
674 (xsd:integer) |
| dbp:pubchemsubstance |
405226665 (xsd:integer) |
| dbp:routesOfAdministration |
dbr:Intravenous_infusion |
| dbp:s |
12 (xsd:integer) |
| dbp:source |
u (en) |
| dbp:synonyms |
PB2452, MEDI2452 (en) |
| dbp:target |
Ticagrelor, AR-C124910XX (en) |
| dbp:type |
mab (en) |
| dbp:unii |
1 (xsd:integer) |
| dbp:wikiPageUsesTemplate |
dbt:Monoclonals_for_bone,_musculoskeletal,_circulatory,_and_neurologic_systems dbt:Infobox_drug dbt:Portal_bar dbt:Redirect dbt:Reflist dbt:Short_description dbt:Blood-drug-stub dbt:Monoclonal-antibody-stub |
| dcterms:subject |
dbc:Antidotes dbc:Monoclonal_antibodies |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody dbo:Drug |
| rdfs:comment |
Bentracimab is a monoclonal antibody medication which has been shown in phase one and two clinical trials to function as a reversal agent for the anti–blood clotting drug ticagrelor (which acts as a P2Y12 inhibitor and is sold under the brand name Brilinta among others). It is under investigation for use in major, life-threatening bleeding in patients being treated with ticagrelor. It is not commercially available. (en) |
| rdfs:label |
Bentracimab (en) |
| owl:sameAs |
wikidata:Bentracimab https://global.dbpedia.org/id/Fm217 |
| prov:wasDerivedFrom |
wikipedia-en:Bentracimab?oldid=1107898866&ns=0 |
| foaf:isPrimaryTopicOf |
wikipedia-en:Bentracimab |
| is dbo:wikiPageRedirects of |
dbr:REVERSE-IT |
| is dbo:wikiPageWikiLink of |
dbr:Idarucizumab dbr:REVERSE-IT |
| is foaf:primaryTopic of |
wikipedia-en:Bentracimab |